

# ULTRAPAR PARTICIPAÇÕES S.A.

**3Q23 Earnings Conference Call** 

11.09.2023

### **Disclaimer**

## Forward-looking statements


✓ This presentation may include forward-looking statements about future events. Such statements reflect only the expectations of the management of the Company. Forward-looking statements may be identified by the use of words such as "anticipate", "believe", "expect", "estimate", "plan", "outlook", "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Investors are cautioned that such forward-looking statements are subject to risks and uncertainties that could cause actual results or outcomes to differ materially from those indicated by such forward-looking statements. For this reason, readers should not place undue emphasis on these forward-looking statements.


## > Standards and criteria adopted in preparing the information


- ✓ In May and August 2021, the sales agreements of Extrafarma and Oxiteno were signed, respectively, according to the Material Notices disclosed at the time. On December 31<sup>st</sup>, 2021, Ultrapar classified these businesses as assets and liabilities held for sale and discontinued operations. The sale of Oxiteno was concluded on April 1<sup>st</sup>, 2022, and thus ceased to be part of discontinued operations and Ultrapar's results as of 2Q22. The sale of Extrafarma was concluded on August 1<sup>st</sup>, 2022, and its results are shown within discontinued operations until this date. In this presentation, the financial information of 2022 related to Ultrapar corresponds to the consolidated information (pro forma) of the Company, that is, the data considers the sum of continuing and discontinued operations, unless otherwise indicated.
- ✓ The financial information presented on this document were extracted from the individual and consolidated interim financial information ("Quarterly Information") for the three months period ended on September 30, 2023, and prepared in accordance with the pronouncement CPC 21 (R1) Interim Financial Reporting and the International Accounting Standard IAS 34 Interim Financial Reporting issued by the International Accounting Standards Board ("IASB"), and presented in accordance with the applicable rules for Quarterly Information, issued by the Brazilian Securities and Exchange Commission ("CVM"). The information related to the businesses are presented without the elimination of intersegment transactions. Therefore, the sum of such information may not correspond to Ultrapar's consolidated information (pro forma). Additionally, the financial and operational information presented in this discussion is subject to rounding and, consequently, the total amounts presented in the tables and charts may differ from the direct numerical sum of the amounts that precede them. Information denominated EBITDA are presented in accordance to Resolution 156, issued by the CVM on June 23, 2022.




## Ultrapar – 3Q23 performance











<sup>&</sup>lt;sup>1</sup> Non-recurring items described on page 2 from Earnings Release

## Ultrapar – Debt and leverage

## Net debt and leverage



Reduction in net debt

Operating cash generation

**Receipt** of the 2<sup>nd</sup> installment from the sale of **Extrafarma** (R\$ 198 M)

Payment of dividends (R\$ 274 M)

Payment of the acquisition of Opla (R\$ 210 M)

Reduction in draft discount

- Reduction of R\$ 294 M vs 2Q23
- Reduction of R\$ 1,387 M vs 3Q22

#### ✓ Reduction in leverage QoQ

- Higher LTM EBITDA from continuing operations
- Lower net debt

### Debt and debt maturity profile

Net debt (IFRS 16)

3Q22 **2Q23** 3Q23 Net debt 7,446 8.007 7.082 Trade payables – reverse factoring (draft discount) 2.561 1.468 1.175 Financial liabilities of customers (vendor)<sup>2</sup> 531 388 354 Receivables from divestments (Oxiteno and Extrafarma) (1,114)(1,083)(932)Net debt + draft discount + vendor + receivables 9,425 8.779 7,679

Net debt (IFRS 16) / LTM EBITDA1




<sup>1</sup> Adjusted LTM EBITDA does not include Extrafarma's impairment, capital gain and closing adjustments from the sales of ConectCar, Oxiteno and Extrafarma, and extraordinary tax credits; furthermore, it does not include the LTM result from Oxiteno and Extrafarma since the closing of the sales




R\$ M

<sup>&</sup>lt;sup>2</sup> Vendor amounts included in the trade payables line in 3Q22

## Ultragaz – 3Q23 performance





#### **Volume 3Q23 x 3Q22**

#### **Bottled**

• Stable between periods

#### Bulk

Higher sales to industries

#### **EBITDA 3Q23 x 3Q22**

**Efficiency** and **productivity** gains


Better sales mix


**Inflation** pass through

Higher expenses



## Ultracargo – 3Q23 performance





#### **Installed capacity**

- +90 thousand m³ **Opla** (Jul-23)
- +12 thousand m³ **Rondonópolis** (Sep-23)
- +10 thousand m³ Vila do Conde (Jul-23)

#### m³ sold

- Higher **handling of fuels** in Itaqui, Santos and Suape
- Start-up of **operations in Opla**

#### Net revenues

Spot sales

Higher m³ sold

Higher tariffs

#### **EBITDA**

Higher occupancy of capacity with profitability gains

**Spot** sales


Higher **tariffs** 

**Productivity** and **efficiency** gains

Higher expenses




## Ipiranga – 3Q23 performance




## **AmPm** evolution

- ✓ Total revenues (GMV¹) of R\$ 500 M (SSS +9% YoY)
- √ 1.542 convenience stores
  - 27% of penetration
- √ 189 company-operated stores



Gross merchandise value



<sup>&</sup>lt;sup>2</sup> Non-recurring items described on page 2 from Earnings Release





## ULTRAPAR PARTICIPAÇÕES S.A.

Investor Relations 55 11 3177-7014 invest@ultra.com.br ri.ultra.com.br